ALHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alignment Healthcare Inc (ALHC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. Despite recent volatility and hedge fund selling, the company's strong revenue growth, positive analyst sentiment, and potential for long-term upside make it an attractive investment opportunity.
The MACD is below zero but negatively contracting, indicating potential stabilization. RSI is neutral at 49.682, showing no overbought or oversold conditions. Moving averages are converging, suggesting a lack of clear trend direction. Key support is at 18.919, and resistance is at 20.869. The stock is trading near its pivot point of 20.124.
Analysts have consistently raised price targets, with the most recent targets ranging from $25 to $30, indicating strong confidence in the stock's future performance.
Q4 2025 revenue grew 45.5% YoY, and full-year revenue increased 46.1% YoY, showcasing robust growth.
Health plan membership increased by 25% YoY, reflecting strong operational performance.
Positive sentiment from analysts regarding the Medicare Advantage trade and Alignment's positioning as a leader in the space.
Hedge funds have significantly increased selling activity, which could indicate short-term bearish sentiment.
Post-market price dropped by 7.49%, reflecting potential short-term volatility.
Net income and EPS declined significantly YoY, showing profitability challenges.
No recent congress trading data or influential figure transactions to support confidence.
In Q4 2025, revenue increased by 44.43% YoY to $1.02 billion, and full-year revenue grew by 46.1% to $3.95 billion. However, net income dropped by 64.60% YoY to -$11.01 million, and EPS decreased by 68.75% to -$0.05. Gross margin improved slightly to 11.4%, up 0.44% YoY. While revenue growth is strong, profitability remains a concern.
Analysts are overwhelmingly positive on ALHC, with multiple firms raising price targets recently. JPMorgan, Baird, KeyBanc, TD Cowen, and Piper Sandler have all increased their targets, with the highest being $30. Analysts highlight strong sales, membership growth, and Alignment's leadership in the Medicare Advantage space as key drivers for their optimism.
